Nature Communications · 7 July 2026 · From issue 03
Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation
Combining two immune drugs worked better than one drug against lung cancer that spread to the brain.
Kazutaka Hosoya, Hiroaki Ozasa et al.
Lung cancer that spreads to the brain often does not respond well to a common immune drug used alone. This study looked at why, using patient data, tissue samples, and mice. Brain tumors had fewer cancer-fighting immune cells and fewer immune cell clusters than the original lung tumors. This may explain why the immune drug struggles to work there. In mice, using two immune drugs together shrank tumors more and helped mice live longer than using just one drug. The two-drug mix also boosted certain helper immune cells and triggered new immune cell clusters to form. In patients, the two-drug combination seemed to control brain tumors better than one drug alone.
Integrity screen: passed (3 checks) Checked 8 July 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue